The cannabis outfit received a warning letter for marketing unapproved CBD products via unsubstantiated claims in its online store and social media, the FDA said.
Novartis looks to settle doc-bribery suit; CEO shares update on Zolgensma coverage
The Swiss drugmaker, which reported an otherwise upbeat second quarter, allocated a substantial reserve to settle bribery charges stemming from the suit.
Trump’s price-disclosure rule is DOA, but not idea to include costs in EHRs
Throughout Men’s Health Month, pharma and healthcare organizations have been using earned, shared and paid media to spur men to break their stereotypical reluctance to talk about health conditions.
Loading...
Culture drives the company
Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more.
Want to read more?
Please login or register first to view this content.
